Anticholinergic agents

Pulmonary Pharmacology and Therapeutics

Volumn 11, Issue 5-6, 1998, Pages 381-392

  Cazzola, M ^c   Centanni, S ^a   Donner, C F ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b Division of Pneumology   (Italy)

^c IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; IPRATROPIUM BROMIDE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC RECEPTOR; PIRENZEPINE; RECEPTOR SUBTYPE; SALBUTAMOL;

AIRWAY OBSTRUCTION; ASTHMA; BREATHING MUSCLE; BRONCHODILATING ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RESPIRATORY FUNCTION; SMOOTH MUSCLE CONTRACTION;

EID: 0005457251     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1006/pupt.1999.0174     Document Type: Conference Paper

References (96)

1. 1. Fryer A D, Jacoby D B. Muscarinic receptors and control of airway smooth muscle. Am J Respir Crit Care Med 1998; 158: S154-S160.
2. 2. Bonner T I. New subtypes of muscarinic acetylcholine receptors. Trends Pharmacol Sci 1989; 10 (Suppl): 11-15.
3. 3. Hulme E C. Muscarinic acetylcholine receptors: typical G-coupled receptors. Symp Soc Exp Biol 1990; 44: 39-54.
4. 4. Habecker B A, Tietje K M, van Koppen C J, Creason S A, Goldman P S, Migeon J C, Parenteau L A, Nathanson N M. Regulation of expression and function of muscarinic receptors. Life Sci 1993; 52: 429-432.
5. 5. Felder C C. Muscarinic acetylcholine receptors: signal transduction through multiple effectors. FASEB J 1995; 9: 619-625.
6. 6. Eglen R M, Reddy H, Watson N. Selective inactivation of muscarinic receptor subtypes. Int J Biochem 1994; 26: 1357-1369.
7. 7. Mak J C, Barnes P J. Autoradiographic visualization of muscarinic receptor subtypes in human and guinea pig lung. Am Rev Respir Dis 1990; 141: 1559-1568.
8. 8. Barnes P J. Muscarinic receptor subtypes in airways. Life Sci 1993; 52: 521-527.
9. 9. Roux E, Molimard M, Savineau J P, Marthan R. Muscarinic stimulation of airway smooth muscle cells. Gen Pharmacol 1998; 31: 349-356.
10. 10. Mak J C, Haddad E B, Buckley N J, Barnes P J. Visualization of muscarinic m4 mRNA and M4 receptor subtype in rabbit lung. Life Sci 1993; 53: 1501-1508.
11. 11. Mak J C, Baraniuk J N, Barnes P J. Localization of muscarinic receptor subtype mRNAs in human lung. Am J Respir Cell Mol Biol 1992; 7: 344-348.
12. 12. Eglen R M, Hegde S S, Watson N. Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev 1996; 48: 531-565.
13. 2 receptors in regulating β-adrenergic responsiveness in maturing rabbit airway smooth muscle. Am J Physiol 1995; 269: L783-L790.
14. 14. Matera M G, Cazzola M, Costantino M, De Santis D, Rossi F. Responsiveness and sensitivity to cholinergic agonists and antagonists in bovine isolated bronchial muscle. Clin Exp Pharmacol Physiol 1992; 19: 627-630.
15. 15. Ortiz J L, Labat C, Norel X, Matera M G, Cortigo J, Morcillo E, Rossi F, Brink C. Contraction of bovine isolated bronchial airways: effects of epithelium removal. Respiration 1993; 60: 351-353.
16. 16. Goldie R G, Fernandes L B, Farmer S G, Jay D W. Airway epithelium-derived inhibitory factor. Trends Pharmacol Sci 1990; 11: 67-70.
17. 17. Cazzola M, Matera M G, Rossi F, Brink C, Girbino G. Espressione funzionale delle sottopopolazioni recettoriali colinergiche dell'epitelio bronchiale. Lotta contro la Tuberc e Mal Polm Soc 1991; 61: 326-332.
18. 1 muscarinic receptor subtypes in mediating airway smooth muscle contraction. Int J Tissue React 1993; 15: 31-35.
19. 19. Orer H S, Guc M O, Rezaki Y E, Ilhan M, Kayaalp S O. Antagonism of acetylcholine action in guinea-pig tracheal smooth muscle and epithelium by pirenzepine, 4-DAMP and atropine. Arch Int Pharmacodyn Ther 1990; 305: 45-54.
20. 20. Morrison K J, Vanhoutte P M. Characterization of muscarinic receptors that mediate contraction of guinea-pig isolated trachea to choline esters: effect of removing epithelium. Br J Pharmacol 1992; 106: 672-676.
21. 21. Patel H J, Barnes P J, Takahashi T, Tadjkarimi S, Yacoub M H, Belvisi M G. Evidence for prejunctional muscarinic autoreceptors in human and guinea pig trachea. Am J Respir Crit Care Med 1995; 152: 872-878.
22. 22. Groeben H, Brown R H. Ipratropium decreases airway size in dogs by preferential M2 muscarinic receptor blockade in vivo. Anesthesiology 1996; 85: 867-873.
23. 23. Faulkner D, Fryer A D, Maclagan J. Postganglionic muscarinic inhibitory receptors in pulmonary parasympathetic nerves in the guinea-pig. Br J Pharmacol 1986; 88: 181-187.
24. 24. Minette P A, Lammers J W, Dixon C M, McCusker M T, Barnes P J. A muscarinic agonist inhibits reflex bronchoconstriction in normal but not in asthmatic subjects. J Appl Physiol 1989; 67: 2461-2465.
25. 25. Fryer A D, Jacoby D B. Muscarinic receptors and control of airway smooth muscle. Am J Respir Crit Care Med 1998; 158: S154-S160.
26. 26. Fryer A D, Jacoby D B. Parainfluenza virus infection damages inhibitory M2 muscarinic receptors on pulmonary parasympathetic nerves in the guinea-pig. Br J Pharmacol 1991; 102: 267-271.
27. 27. Fryer A D, El-Fakahany E E, Jacoby D B. Parainfluenza virus type 1 reduces the affinity of agonists for muscarinic receptors in guinea-pig lung and heart. Eur J Pharmacol 1990; 181: 51-58.
28. 28. Kahn R M, Okanlami O A, Jacoby D B, Fryer A D. Viral infection induces dependence of neuronal M2 muscarinic receptors on cyclooxygenase in guinea pig lung. J Clin Invest 1996; 98: 299-307.
29. 29. Schultheis A H, Bassett D J, Fryer A D. Ozone-induced airway hyperresponsiveness and loss of neuronal M2 muscarinic receptor function. J Appl Physiol 1994; 76: 1088-1097.
30. 2-muscarinic receptors in pulmonary parasympathetic nerves after antigen challenge. J Appl Physiol 1991; 71: 2255-2261.
31. 31. Gleich G J, Jacoby D B, Fryer A D. Eosinophil-associated inflammation in bronchial asthma: a connection to the nervous system. Int Arch Allergy Immunol 1995; 107: 205-207.
32. 2 muscarinic receptors in antigen-challenged guinea pigs is restored by heparin and poly-L-glutamate. J Clin Invest 1992; 90: 2292-2298.
33. 33. Ichinose M, Miura M, Tomaki M, Oyake T, Kageyama N, Ikarashi Y, Maruyama Y, Shirato K. Incubation with IgE increases cholinergic neurotransmission in human airways in vitro. Am J Respir Crit Care Med 1996; 154: 1272-1276.
34. 2 receptors. Life Sci 1997; 60: 1015-1021.
35. 35. Cazzola M, Russo S, De Santis D, Principe P, Marmo E. Respiratory responses to pirenzepine in healthy subjects. Int J Clin Pharmacol Ther Toxicol 1987; 25: 105-109.
36. 36. Cazzola M, Matera M G, D'Amato G, De Santis D, Maione S, Lisa M, Cenicola M L, Marmo E. Evidence of muscarinic receptor subtypes in airway smooth muscle of normal volunteers and of chronic obstructive pulmonary disease patients. Int J Clin Pharmacol Res 1989; 9: 65-70.
37. 1-selective muscarinic receptor antagonist telenzepine improves lung function in patients with chronic obstructive bronchitis. Pulm Pharmacol 1990; 3: 185-189.
38. 38. Ceyhan B, Celikel T, Simsir S, Kandemir B. Comparison of the bronchodilator efficacy of nebulized pirenzepine and ipratropium bromide in patients with airway obstructive lung disease. Int J Clin Pharmacol Ther Toxicol 1993; 31: 510-513.
39. 39. Cazzola M, Matera M G, Santangelo G, Guidetti E, Rossi F. Nebulized pirenzepine does not induce bronchodilation in patients with COPD. Eur Respir J 1992; 5 (Suppl 15): S212.
40. 1-receptor-selective antagonist, telenzepine, had no bronchodilatory effects in COPD patients. Eur Respir J 1993; 6: 378-382.
41. 41. Cazzola M, Matera M G, D'Amato G, De Novellis V, Marmo E. Muscarinic M-1 receptors mediate the bronchial hyperresponsiveness during methacholine inhalation. Int J Clin Pharmacol Res 1989; 9: 71-76.
42. 1) muscarinic receptors in vagally mediated bronchoconstriction in humans. Am Rev Respir Dis 1989; 139: 446-449.
43. 43. Barnes P J. Muscarinic receptor subtypes in airways. Eur Respir J 1993; 6: 328-331.
44. 1-selective muscarinic receptor antagonist, in patients with nocturnal asthma. Pulm Pharmacol 1994; 7: 91-97.
45. 45. Newcomb R, Tashkin D P, Hui K K, Conolly M E, Lee E, Dauphinee B. Rebound hyperresponsiveness to muscarinic stimulation after chronic therapy with an inhaled muscarinic antagonist. Am Rev Respir Dis 1985; 132: 12-15.
46. 46. Wilding P J, Clark M M, Pavord I D, Parker D, Bennett J A, Tattersfield A E. Effect of cessation of short-term therapy with ipratropium bromide on lung function and airway responsiveness. Eur Respir J 1996; 9: 1627-1631.
47. 47. Witt-Enderby P A, Yamamura H I, Halonen M, Lai J, Palmer J D, Bloom J W. Regulation of airway muscarinic cholinergic receptor subtypes by chronic anticholinergic treatment. Mol Pharmacol 1995; 47: 485-490.
48. 48. Bauer R, Banholzer R. Pharmacology of quaternary anticholinergic drugs. In: Gross N J, ed. Anticholinergic Therapy in Obstructive Airway Disease. London: Franklin Scientific Publications, 1993: 105-115.
49. 49. Gross N J, Skorodin M S. Anticholinergic, antimuscarinic bronchodilators. Am Rev Respir Dis 1984; 129: 856-870.
50. 50. Chapman K R. The role of anticholinergic bronchodilators in adult asthma and chronic obstructive pulmonary disease. Lung 1990; 168 (Suppl): 295-303.
51. 51. van Schayck C P, van Weel C, Folgering H, Verbeek A L, van Herwaarden C L. Treatment of patients with airflow obstruction by general practitioners and chest physicians. Scand J Prim Health Care 1989; 7: 137-142.
52. 52. van Schayck C P, Folgering H, Harbers H, Maas K L, van Weel C. Effects of allergy and age on responses to salbutamol and ipratropium bromide in moderate asthma and chronic bronchitis. Thorax 1991; 46: 355-359.
53. 53. Thiessen B, Pedersen O F. Maximal expiratory flows and forced vital capacity in normal, asthmatic and bronchitic subjects after salbutamol and ipratropium bromide. Respiration 1982; 43: 304-316.
54. 54. Barnes P J. Theoretical aspects of anticholinergic treatment. In: Gross N J, ed. Anticholinergic Therapy in Obstructive Airway Disease. London: Franklin Scientific Publications, 1993: 88-104.
55. 55. Barnes P J. Neuroeffector mechanisms: the interface between inflammation and neuronal responses. J Allergy Clin Immunol 1996; 98: S73-S81.
56. 56. Barnes P J. Airway inflammation and autonomic control. Eur J Respir Dis 1986; 147 (Suppl): 80-87.
57. 57. Endoh N, Ichinose M, Takahashi T, Miura M, Kageyama N, Mashito Y, Sugiura H, Ikeda K, Takasaka T, Shirato K. Relationship between cholinergic airway tone and serum immunoglobulin E in human subjects. Eur Respir J 1998; 12: 71-74.
58. 58. Jolobe O M. Impaired atropine responsiveness in asthma: role of atopy. Respiration 1983; 44: 97-102.
59. 59. Ullah M I, Newman G B, Saunders K B. Influence of age on response to ipratropium and salbutamol in asthma. Thorax 1981; 36: 523-529.
60. 60. Jolobe O M. Asthma vs. non-specific reversible airflow obstruction: clinical features and responsiveness to anticholinergic drugs. Respiration 1984; 45: 237-242.
61. 61. Morrison J F, Pearson S B. The effect of the circadian rhythm of vagal activity on bronchomotor tone in asthma. Br J Clin Pharmacol 1989; 28: 545-549.
62. 62. Morrison J F, Pearson S B, Dean H G. Parasympathetic nervous system in nocturnal asthma. Br Med J 1988; 296: 1427-1429.
63. 63. Morrison J F, Pearson S B. The parasympathetic nervous system and the diurnal variation of lung mechanics in asthma. Respir Med 1991; 85: 285-289.
64. 64. Bellia V, Ferrara G, Cibella F, Cuttitta G, Visconti A, Insalaco G, Mirto M, Peralta G. Comparison of the effect of oxitropium bromide and of slow-release theophylline on nocturnal asthma. Postgrad Med J 1988; 64: 583-586.
65. 65. Hughes D T. The use of anticholinergic drugs in nocturnal asthma. Postgrad Med J 1987; 63 (Suppl 1): 47-51.
66. 66. Sly P D, Landau L I, Olinsky A. Failure of ipratropium bromide to modify the diurnal variation of asthma in asthmatic children. Thorax 1987; 42: 357-360.
67. 67. Cazzola M, Matera M G, D'Amato G, Rossi F. Asma notturno. Modello di trattamento. Rif Med 1992; 107: 9-17.
68. 68. Ward M J, Fentem P H, Smith W H, Davies D. Ipratropium bromide in acute asthma. Br Med J 1981; 282: 598-600.
69. 69. Ward M J. The role of anticholinergic agents in acute asthma. In: Gross N J, ed. Anticholinergic Therapy in Obstructive Airway Disease. London: Franklin Scientific Publications, 1993: 155-162.
70. 70. Lanes S F, Garrett J E, Wentworth C E 3rd, Fitzgerald J M, Karpel J P. The effect of adding ipratropium bromide to salbutamol in the treatment of acute asthma: a pooled analysis of three trials. Chest 1998; 114: 365-372.
71. 71. Garrett J E. Combined anticholinergic therapy in the management of acute asthma. Respirology 1997; 2 (Suppl 1): S17-S18.
72. 72. Fitzgerald J M, Grunfeld A, Pare P D, Levy R D, Newhouse M T, Hodder R, Chapman K R. The clinical efficacy of combination nebulized anticholinergic and adrenergic bronchodilators vs nebulized adrenergic bronchodilator alone in acute asthma. Canadian Combivent Study Group. Chest 1997; 111: 311-315.
73. 1. The Lung Health Study. JAMA 1994; 272: 1497-1505.
74. 74. Ferguson G T, Cherniack R M. Management of chronic obstructive pulmonary disease. N Engl J Med 1993; 328: 1017-1022.
75. 75. Rennard S I, Serby C W, Ghafouri M, Johnson P A, Friedman M. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. Chest 1996; 110: 62-70.
76. 76. Cazzola M, Spina D, Matera M G. The use of bronchodilators in stable chronic obstructive pulmonary disease. Pulm Pharmacol Ther 1997; 10: 129-144.
77. 77. Wright J L. Small airway disease: structure and function. In: Hensley M J, Saunders N A, eds. Clinical Epidemiology of Chronic Obstructive Pulmonary Disease. New York: Marcel Dekker, 1989: 55-80.
78. 78. Ohrui T, Yanei M, Sekiwzawa K, Morikawa M, Sasaki H, Takishima T. Effective site of bronchodilation by beta-adrenergic and anticholinergic agents in patients with chronic obstructive pulmonary disease: direct measurement of intrabronchial pressure with a new catheter. Am Rev Respir Dis 1992; 146: 88-91.
79. 79. Carstairs J R, Nimmo A J, Barnes P J. Autoradiographic visualization of beta-adrenoceptor subtypes in human lung. Am Rev Respir Dis 1985; 132: 541-547.
80. 80. Matera M G, Cazzola M, Vinciguerra A, Di Perna F, Calderaro F, Caputi M, Rossi F. A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1995; 8: 267-271.
81. 81. Anderson W, Wisniewski M, Barbee R, Rickard K, for the COPD Clinical Investigators. A comparison of Serevent and ipratropium on pulmonary function in COPD patients reversible to ipratropium. Am J Respir Crit Care Med 1997; 155: A278.
82. 82. Ikeda A, Nishimura K, Koyama H, Izumi T. Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease. Thorax 1995; 50: 62-66.
83. 83. Cazzola M, Matera M G, Di Perna F, Calderaro F, Califano C, Vinciguerra A. A comparison of bronchodilating effects of salmeterol and oxitropium bromide in stable chronic obstructive pulmonary disease. Respir Med 1998; 92: 354-357.
84. 84. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994; 105: 1411-1419.
85. 85. Matera M G, Caputi M, Cazzola M. A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease. Respir Med 1996; 90: 497-499.
86. 86. van Noord J A, de Munck D R A J, Bantje Th A, Hop W C J, Bommer A M. Efficacy and safety of salmeterol xinafoate and ipratropium bromide in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: A799.
87. 87. Cazzola M, Di Perna F, Noschese P, Vinciguerra A, Calderaro F, Girbino G, Matera M G. Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD. Eur Respir J 1998; 11: 1337-1341.
88. 88. Karpel J P. Bronchodilator responses to anticholinergic and beta-adrenergic agents in acute and stable COPD. Chest 1991; 99: 871-876.
89. 89. Fernandez A, Lazaro A, Garcia A, Aragon C, Cerda E. Bronchodilators in patients with chronic obstructive pulmonary disease on mechanical ventilation. Utilization of metered-dose inhalers. Am Rev Respir Dis 1990; 141: 164-168.
90. 90. Patrick D M, Dales R E, Stark R M, Laliberte G, Dickinson G. Severe exacerbations of COPD and asthma. Incremental benefit of adding ipratropium to usual therapy. Chest 1990; 98: 295-297.
91. 91. Kuhl D A, Agiri O A, Mauro L S. Beta-agonists in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Ann Pharmacother 1994; 28: 1379-1388.
92. 3 receptors. J Recept Signal Transduct Res 1997; 17: 177-184.
93. 3 antagonists for clinical use. Life Sci 1997; 60: 1053-1060.
94. 3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Mol Pharmacol 1994; 45: 899-907.
95. 95. Maesen F P, Smeets J J, Sledsens T J, Wald F D, Cornelissen P J. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. Eur Respir J 1995; 8: 1506-1513.
96. 96. O'Connor B J, Towse L J, Barnes P J. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med 1996; 154: 876-880.